Keyphrases
Migraine
93%
Post-traumatic Headache
67%
Calcitonin Gene-related Peptide
42%
Headache
42%
Mild Traumatic Brain Injury (mTBI)
33%
Meta-analysis
27%
Migraine Attack
26%
Migraine without Aura (MWoA)
24%
Systematic Meta-analysis
24%
Migraine-like
21%
Placebo
19%
Clinical Features
15%
Erenumab
15%
Relative Frequency
14%
Traumatic Brain Injury
13%
Healthy Controls
13%
Chronic Migraine
12%
Preventive Treatment
10%
Primary Headache
10%
Premonitory Symptoms
10%
Cluster Headache
9%
Clinical Characteristics
9%
Monthly Migraine Days
9%
Migraine Pathophysiology
9%
Tension-type Headache
8%
Posttraumatic Stress Disorder
8%
Cromakalim
8%
Randomized Clinical Trial
8%
Migraine Patients
8%
Migraine Prevention
7%
Placebo-controlled
7%
Neck Pain
7%
Epidemiology
7%
Risk Factors
6%
Headache Intensity
6%
Embase
6%
Human Model
6%
Calcitonin Receptor
6%
Hemicrania Continua
6%
ATP-sensitive Potassium Channel
6%
Plasma Parameters
6%
Whiplash Injury
6%
Bench to Bedside
6%
MRI Study
6%
Human Models of Migraine
6%
Pituitary Adenylate Cyclase-activating polypeptide-38
6%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
6%
Area under the Curve
6%
PubMed
5%
Randomized Controlled Trial
5%
Medicine and Dentistry
Migraine
85%
Posttraumatic Headache
52%
Headache
46%
Systematic Review
33%
Traumatic Brain Injury
28%
Calcitonin Gene Related Peptide
28%
Clinical Feature
21%
Meta-Analysis
21%
Cohort Effect
16%
Hypersensitivity
12%
Placebo
12%
Symptom
12%
Prevalence
12%
Transformed Migraine
10%
Erenumab
9%
Disease
8%
Migraine with Aura
7%
Biological Marker
7%
Tension Headache
7%
Primary Headache
7%
Sequela
6%
Whiplash Injury
6%
Cluster Headache
6%
Hemicrania Continua
6%
Neck Pain
6%
Migraine Aura
6%
Magnetic Resonance Imaging
6%
Auras
5%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Headache
56%
Calcitonin Gene Related Peptide
39%
Posttraumatic Headache
39%
Placebo
26%
Traumatic Brain Injury
26%
Erenumab
17%
Erethism
17%
Adenosine Triphosphate Sensitive Potassium Channel
15%
Transformed Migraine
13%
Lemakalim
12%
Clinical Feature
9%
Symptom
9%
Primary Headache
8%
Tension Headache
7%
Randomized Controlled Trial
7%
Pharmacotherapy
7%
Observational Study
6%
Normal Human
6%
Prevalence
6%
Cluster Headache
6%
Calcitonin Gene Related Peptide Receptor
6%
Posttraumatic Stress Disorder
6%
Hemicrania Continua
6%
Hypophysis Adenylate Cyclase Activating Polypeptide
6%
Pathophysiology
5%
Randomized Clinical Trial
5%
Monoclonal Antibody
5%
Receptor
5%
